{
    "clinical_study": {
        "@rank": "8445", 
        "brief_summary": {
            "textblock": "To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the\n      treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with the\n      established therapy BV (bleomycin/vincristine). To evaluate the safety and tolerance of\n      DOX-SL compared to BV in a population of AIDS patients with moderate to severe KS."
        }, 
        "brief_title": "Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "AIDS-Related Opportunistic Infections", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive either DOX-SL or the BV combination. Infusions are given\n      on day 1 and every 3 weeks for a total of six cycles. Kaposi's sarcoma lesions are evaluated\n      prior to every cycle, at the end of the last treatment cycle, and 4 weeks following the end\n      of the last treatment. Patients who respond to therapy will be followed every 2 months for\n      up to 1 year. Patients must agree to have one or more representative KS lesions biopsied."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Prophylaxis for PCP, cryptococcal, and herpes infections, and antiretroviral therapy\n             (e.g., AZT, ddC, ddI) provided these doses have been stable for at least 1 month.\n\n          -  Maintenance therapy for tuberculosis, fungal, and herpes infections.\n\n          -  Therapy for new episodes of tuberculosis, fungal, and herpes infection except with\n             potentially myelotoxic chemotherapy.\n\n          -  Foscarnet for cytomegalovirus infection.\n\n          -  Erythropoietin.\n\n        Patients must have:\n\n          -  Biopsy-proven, progressive, AIDS-related Kaposi's sarcoma, with any of the following:\n\n          -  At least 15 mucocutaneous lesions.\n\n          -  Six or more new lesions in the prior month.\n\n          -  Documented visceral disease with at least five accessible cutaneous lesions.\n\n          -  Documented anti-HIV antibody.\n\n          -  No active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma,\n             Pneumocystis carinii, or other microorganisms (if REQUIRING treatment with myelotoxic\n             drugs).\n\n          -  Life expectancy > 4 months.\n\n        NOTE:\n\n          -  Patients who fail the BV combination or who relapse are eligible to enter the\n             Liposome Technology open trial using DOX-SL alone.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Clinically significant cardiac disease.\n\n          -  Confusion, disorientation, CNS symptoms, or peripheral neuropathy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other cytotoxic chemotherapy.\n\n          -  Colony-stimulating factors.\n\n          -  Ganciclovir.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Prior neoplasms treated with extensive chemotherapy that, in the investigator's\n             opinion, has led to irreversibly compromised bone marrow function.\n\n          -  History of idiosyncratic or allergic reaction to anthracyclines, bleomycin, or\n             vincristine.\n\n          -  History of major psychiatric illness.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Cytotoxic chemotherapy or interferon therapy within the past 4 weeks.\n\n          -  More than one prior cycle of bleomycin/vincristine at any time.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiation or electron beam therapy within the past 3 weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "220", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002105", 
            "org_study_id": "134B", 
            "secondary_id": "LTI-30-11"
        }, 
        "intervention": [
            {
                "intervention_name": "Doxorubicin hydrochloride (liposomal)", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Bleomycin sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Vincristine sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bleomycin", 
                "Doxorubicin", 
                "Vincristine"
            ]
        }, 
        "keyword": [
            "Vincristine", 
            "Sarcoma, Kaposi", 
            "Liposomes", 
            "Doxorubicin", 
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "Bleomycin", 
            "Drug Carriers"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77074"
                    }, 
                    "name": "Twelve Oaks Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "Virginia Mason Research Center / Clinical Trial Unit"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "citation": "Stewart S, Jablonowski H, Goebel FD, L'Age M, Spittle M, Luthy R. Randomized comparative trial of DOXIL vs. Bleomycin and Vincristine in the treatment of AIDS-Related KS. Int Conf AIDS. 1996 Jul 7-12;11(Program Supplement):27 (abstract no LBB6026)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002105"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sequus Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1996"
    }, 
    "geocoordinates": {
        "Beth Israel Hosp": "42.358 -71.06", 
        "Mount Sinai Med Ctr": "40.714 -74.006", 
        "Twelve Oaks Hosp": "29.76 -95.369", 
        "Virginia Mason Research Center / Clinical Trial Unit": "47.606 -122.332"
    }
}